Abstract
Clinical effect of drugs is influenced by the composition of the pharmaceutical preparation but substantially by the fate of the drug in the body. Metabolism of the xenobiotic drug compounds may result in pharmacologically inactive metabolites, however, metabolites with higher pharmacological activity can also be produced. These active metabolites may have different pharmacokinetic properties than the parent drug. Co-existience of the parent drug and the active metabolite in the body may significantly modify the therapeutic effect. Knowledge-based system of pharmacokinetics and metabolism of the drugs has a high impact in understanding both the pharmacokinetic and the pharmacodynamic interactions. Cytochrome P450 isoenzymes taking part in the metabolic activity of the central nervous system is a developing area in metabolic studies. In the present study CYP isoenzymes with significant activity in the brain and the clinically important pharmacokinetic and metabolic data of antidepressive compounds are summarized.
Original language | Hungarian |
---|---|
Pages (from-to) | 103-110 |
Number of pages | 8 |
Journal | Neuropsychopharmacologia Hungarica |
Volume | 13 |
Issue number | 2 |
Publication status | Published - Jun 2011 |
Fingerprint
ASJC Scopus subject areas
- Neuroscience(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
- Neuropsychology and Physiological Psychology
- Clinical Neurology
Cite this
Antidepresszánsok és aktív metabolitjaik sorsa a szervezetben. / Tekes, K.; Hashemi, Farzad; Szegi, Péter; Sótónyi, P.; Laufer, Rudolf; Kalász, H.
In: Neuropsychopharmacologia Hungarica, Vol. 13, No. 2, 06.2011, p. 103-110.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antidepresszánsok és aktív metabolitjaik sorsa a szervezetben
AU - Tekes, K.
AU - Hashemi, Farzad
AU - Szegi, Péter
AU - Sótónyi, P.
AU - Laufer, Rudolf
AU - Kalász, H.
PY - 2011/6
Y1 - 2011/6
N2 - Clinical effect of drugs is influenced by the composition of the pharmaceutical preparation but substantially by the fate of the drug in the body. Metabolism of the xenobiotic drug compounds may result in pharmacologically inactive metabolites, however, metabolites with higher pharmacological activity can also be produced. These active metabolites may have different pharmacokinetic properties than the parent drug. Co-existience of the parent drug and the active metabolite in the body may significantly modify the therapeutic effect. Knowledge-based system of pharmacokinetics and metabolism of the drugs has a high impact in understanding both the pharmacokinetic and the pharmacodynamic interactions. Cytochrome P450 isoenzymes taking part in the metabolic activity of the central nervous system is a developing area in metabolic studies. In the present study CYP isoenzymes with significant activity in the brain and the clinically important pharmacokinetic and metabolic data of antidepressive compounds are summarized.
AB - Clinical effect of drugs is influenced by the composition of the pharmaceutical preparation but substantially by the fate of the drug in the body. Metabolism of the xenobiotic drug compounds may result in pharmacologically inactive metabolites, however, metabolites with higher pharmacological activity can also be produced. These active metabolites may have different pharmacokinetic properties than the parent drug. Co-existience of the parent drug and the active metabolite in the body may significantly modify the therapeutic effect. Knowledge-based system of pharmacokinetics and metabolism of the drugs has a high impact in understanding both the pharmacokinetic and the pharmacodynamic interactions. Cytochrome P450 isoenzymes taking part in the metabolic activity of the central nervous system is a developing area in metabolic studies. In the present study CYP isoenzymes with significant activity in the brain and the clinically important pharmacokinetic and metabolic data of antidepressive compounds are summarized.
KW - Active metabolite
KW - Antidepressant
KW - Cyp isoenzymes in brain
KW - Pharmacodynamic interaction
KW - Pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=79959831909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959831909&partnerID=8YFLogxK
M3 - Article
C2 - 21677324
AN - SCOPUS:79959831909
VL - 13
SP - 103
EP - 110
JO - Neuropsychopharmacologia Hungarica
JF - Neuropsychopharmacologia Hungarica
SN - 1419-8711
IS - 2
ER -